{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:18:46Z","timestamp":1790291926663,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Calcitonin gene-related peptide (CGRP) inhibitors have been developed as options for treatment of chronic and episodic migraine. We present our experience of the use of erenumab in a tertiary headache centre.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a prospective clinical audit of all patients commenced on erenumab following a locally agreed pathway and criteria over a consecutive period. Patients received monthly erenumab 140\u00a0mg for 3\u00a0months. Data were collected prospectively at baseline and 3\u00a0months follow up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred three patients were commenced on erenumab during the study period. Patients had tried a median of 7 previous prophylactics, including onabotulinum toxin A in 94%. At 3\u00a0months there was a reduction in median total (28 to 20, 29% reduction, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and severe (15 to 5, 67% reduction, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) headache days. 39.8% of patients achieved at least a 30% reduction in total headache days; 61.8% of patients achieved at least a 50% reduction in severe headache days. Meeting either of these thresholds was considered a positive response, 68% of patients achieved this. Presence of daily headache pattern was negatively associated with response, (56% response vs. 90% without daily headache, <jats:italic>p<\/jats:italic>\u2009=\u20090.0003). There was no association between age, gender, presence of medication overuse or number of previously tried prophylactic treatments and response to erenumab. 43% of patients reported at least one adverse effect, most commonly constipation (26%); treatment was discontinued in 3 patients due to adverse effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Erenumab was an effective treatment for chronic migraine in this treatment resistant population over 3\u00a0months of follow up. Presence of daily headache predicted poorer response but there was still a significant positive response rate in this group.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01456-2","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T04:02:23Z","timestamp":1658462543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of erenumab and factors predicting response after 3\u00a0months in treatment resistant chronic migraine: a clinical service evaluation"],"prefix":"10.1186","volume":"23","author":[{"given":"Michael","family":"Lowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Gorrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the NHS Greater Glasgow and Clyde Headache Service","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"1456_CR1","doi-asserted-by":"publisher","unstructured":"Olesen J, Steiner TJ, Bendtsen L, et al (2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1456_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1177\/0333102420944842","volume":"40","author":"AH Seddik","year":"2020","unstructured":"Seddik AH, Branner JC, Ostwald DA et al (2020) The socioeconomic burden of migraine: An evaluation of productivity losses due to migraine headaches based on a population study in Germany. Cephalalgia 40:1551\u20131560. https:\/\/doi.org\/10.1177\/0333102420944842","journal-title":"Cephalalgia"},{"key":"1456_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M et al (2017) Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev 97:553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015","journal-title":"Physiol Rev"},{"key":"1456_CR4","unstructured":"Scottish Medicines Consortium (2019) SMC2134 Erenumab 70mg solution for injection in pre-filled pen (Amiovig). https:\/\/www.scottishmedicines.org.uk\/media\/4317\/erenumab-aimovig-final-march-2019-amended-030419-for-website.pdf. Accessed 28 Jan 2022"},{"key":"1456_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M et al (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:1\u201310. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"key":"1456_CR6","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N et al (2020) Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine. Headache 60:2014\u20132025. https:\/\/doi.org\/10.1111\/head.13951","journal-title":"Headache"},{"key":"1456_CR7","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1111\/ene.15075","volume":"28","author":"LS de Vries","year":"2021","unstructured":"de Vries LS, Verhagen IE, van den Hoek TC et al (2021) Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study. Eur J Neurol 28:4194\u20134203. https:\/\/doi.org\/10.1111\/ene.15075","journal-title":"Eur J Neurol"},{"key":"1456_CR8","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in Chronic Migraine: An Australian Experience. Headache 60:2555\u20132562. https:\/\/doi.org\/10.1111\/head.13968","journal-title":"Headache"},{"key":"1456_CR9","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL et al (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38:1611\u20131621. https:\/\/doi.org\/10.1177\/0333102418788347","journal-title":"Cephalalgia"},{"key":"1456_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"key":"1456_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:1\u201311. https:\/\/doi.org\/10.1186\/s10194-020-01102-9","journal-title":"J Headache Pain"},{"key":"1456_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61:363\u2013372. https:\/\/doi.org\/10.1111\/head.14032","journal-title":"Headache"},{"key":"1456_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-019-1054-4","volume":"20","author":"R Ornello","year":"2019","unstructured":"Ornello R, Tiseo C, Frattale I et al (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain 20:99. https:\/\/doi.org\/10.1186\/s10194-019-1054-4","journal-title":"J Headache Pain"},{"key":"1456_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.2260","volume":"11","author":"C Baraldi","year":"2021","unstructured":"Baraldi C, Lo CF, Cainazzo MM et al (2021) Predictors of response to erenumab after 12 months of treatment. Brain Behav 11:1\u20138. https:\/\/doi.org\/10.1002\/brb3.2260","journal-title":"Brain Behav"},{"key":"1456_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache 61:1351\u20131363. https:\/\/doi.org\/10.1111\/head.14194","journal-title":"Headache"},{"key":"1456_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/25158163211026646","volume":"4","author":"H Salem-Abdou","year":"2021","unstructured":"Salem-Abdou H, Simonyan D, Puymirat J (2021) Identification of predictors of response to Erenumab in a cohort of patients with migraine. Cephalalgia Reports 4:1\u20138. https:\/\/doi.org\/10.1177\/25158163211026646","journal-title":"Cephalalgia Reports"},{"key":"1456_CR17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/nejmoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2017) A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 377:2123\u20132132. https:\/\/doi.org\/10.1056\/nejmoa1705848","journal-title":"N Engl J Med"},{"key":"1456_CR18","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280\u20132287. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0","journal-title":"Lancet"},{"key":"1456_CR19","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"key":"1456_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14740338.2021.1933941","volume":"20","author":"CI Deligianni","year":"2021","unstructured":"Deligianni CI, Mitsikostas DD, Ashina M (2021) Safety and tolerability evaluation of erenumab for the preventive treatment of migraine. Expert Opin Drug Saf 20:867\u2013876. https:\/\/doi.org\/10.1080\/14740338.2021.1933941","journal-title":"Expert Opin Drug Saf"},{"key":"1456_CR21","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: A retrospective cohort study. Cephalalgia 40:1511\u20131522. https:\/\/doi.org\/10.1177\/0333102420946725","journal-title":"Cephalalgia"},{"key":"1456_CR22","unstructured":"European Medicines Agency (2021) Amiovig: EPAR - Product Information. Annex 1 - Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aimovig. Accessed 28 Jan 2022"},{"key":"1456_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-017-0807-1","volume":"18","author":"M Deen","year":"2017","unstructured":"Deen M, Correnti E, Kamm K et al (2017) Blocking CGRP in migraine patients \u2013 a review of pros and cons. J Headache Pain 18:1\u20139. https:\/\/doi.org\/10.1186\/s10194-017-0807-1","journal-title":"J Headache Pain"},{"key":"1456_CR24","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/head.14198","volume":"61","author":"ID Breen","year":"2021","unstructured":"Breen ID, Mangold AR, VanderPluym JH (2021) The evolving understanding of risk with calcitonin gene-related peptide monoclonal antibodies based on real-world data: A focus on hypertension and Raynaud phenomenon. Headache 61:1274\u20131276. https:\/\/doi.org\/10.1111\/head.14198","journal-title":"Headache"},{"key":"1456_CR25","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/head.14208","volume":"61","author":"DW Dodick","year":"2021","unstructured":"Dodick DW, Tepper SJ, Ailani J et al (2021) Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data. Headache 61:1411\u20131420. https:\/\/doi.org\/10.1111\/head.14208","journal-title":"Headache"},{"key":"1456_CR26","unstructured":"U.S. Food & Drug Administration (2021) Aimovig: Full Prescribing Information. Supplement 11 Label. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=761077. Accessed 28 Jan 2022"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01456-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T04:02:28Z","timestamp":1658462548000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01456-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1456"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01456-2","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"30 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ML reports no disclosures. LM has received speaker honoraria for training and educational events, provided consultancy services for advisory boards and received conference sponsorship from Arvelle Therapeutics UK, Biogen Idec, CSL Behring, GW Pharma, Merck and Teva UK. AT has received grants for attending meetings, has attended advisory boards and participated in satellite symposia organised by Novartis, Teva UK, Lilly and Lundbeck. He was a principle investigator in a randomised clinical trial of erenumab funded by Amgen. GG was a sub-investigator in a randomised clinical trial of erenumab funded by Amgen. SM has received speaker honoraria from Teva UK. KD has received funding\u00a0from Novartis and Allergan\u00a0for attendance at educational meetings, from Allergan for chairing an education meeting,\u00a0and participated in\u00a0a Chronic Migraine Educational Steering committee sponsored by Allergan.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}